Manoj Maniar
Overview
Explore the profile of Manoj Maniar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
331
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Russ E, Fatanmi O, Wise S, Carpenter A, Maniar M, Iordanskiy S, et al.
Sci Rep
. 2024 Feb;
14(1):4518.
PMID: 38402257
Exposure to ionizing radiation (IR) presents a formidable clinical challenge. Total-body or significant partial-body exposure at a high dose and dose rate leads to acute radiation syndrome (ARS), the complex...
2.
Carpenter A, Li Y, Janocha B, Wise S, Fatanmi O, Maniar M, et al.
J Proteome Res
. 2023 Mar;
22(4):1116-1126.
PMID: 36977373
There are currently four radiation medical countermeasures that have been approved by the United States Food and Drug Administration to mitigate hematopoietic acute radiation syndrome, all of which are repurposed...
3.
Li Y, Girgis M, Wise S, Fatanmi O, Seed T, Maniar M, et al.
Sci Rep
. 2021 Jun;
11(1):11449.
PMID: 34075191
To date, the United States Food and Drug Administration (FDA) has approved four drugs to mitigate hematopoietic acute radiation syndrome and all four are repurposed radiomitigators. There are several additional...
4.
Navada S, Garcia-Manero G, OdchimarReissig R, Pemmaraju N, Alvarado Y, Ohanian M, et al.
Leuk Res
. 2020 May;
94:106369.
PMID: 32442785
Phase 1 results from a Phase 1/2 study comprise 18 patients with myelodysplastic syndromes (MDS; n = 9), acute myeloid leukemia (AML; n = 8), and chronic myelomonocytic leukemia (CMML;...
5.
Mudunuru J, Ren C, Taft D, Maniar M
Eur J Drug Metab Pharmacokinet
. 2019 Feb;
44(4):531-538.
PMID: 30701428
Background And Objectives: ON 123300, a small molecule dual inhibitor of the c-MYC activated kinases ARK5 and CDK4/6, is being developed as a novel drug candidate for the treatment of...
6.
Patel H, Maniar M, Ren C, Dave R
AAPS PharmSciTech
. 2017 Jun;
19(1):93-100.
PMID: 28600665
Rigosertib is a novel anticancer drug in clinical development by Onconova therapeutics, Inc. Currently, it is in pivotal phase III clinical trials for myelodysplastic syndrome (MDS) patients. Chemically, it is...
7.
Silverman L, Greenberg P, Raza A, Olnes M, Holland J, Reddy P, et al.
Hematol Oncol
. 2014 Apr;
33(2):57-66.
PMID: 24777753
Rigosertib (ON 01910.Na) is an inhibitor of the phosphoinositide 3-kinase and polo-like kinase pathways that induces mitotic arrest and apoptosis in neoplastic cells, while sparing normal cells. Our purpose is...
8.
Bowles D, Diamond J, Lam E, Weekes C, Astling D, Anderson R, et al.
Clin Cancer Res
. 2014 Feb;
20(6):1656-65.
PMID: 24493827
Purpose: To determine the pharmacokinetics (PK), maximum tolerated dose (MTD), safety, and antitumor activity of an oral formulation of rigosertib, a dual phosphoinositide 3-kinase (PI3K) and polo-like kinase 1 (Plk1)...
9.
Ohnuma T, Lehrer D, Ren C, Cho S, Maniar M, Silverman L, et al.
Am J Cancer Res
. 2013 Jul;
3(3):323-38.
PMID: 23841031
Rigosertib (ON 01910.Na), a synthetic novel benzyl styryl sulfone, was administered to 28 patients with advanced cancer in a Phase I trial in order to characterize its pharmacokinetic profile, determine...
10.
Komrokji R, Raza A, Lancet J, Ren C, Taft D, Maniar M, et al.
Br J Haematol
. 2013 Jun;
162(4):517-24.
PMID: 23789936
The multi-kinase inhibitor rigosertib (ON 01910.Na) induces mitotic arrest and apoptosis in myeloblasts, while sparing normal cells. The purpose of this study was to determine the pharmacokinetic profile, maximum-tolerated dose...